Raltegravir Potassium Form 3 Crystallization Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing processes for preparing crystalline Raltegravir potassium Form 3 suffer from reproducibility issues, contamination by other polymorphs, excessive solvent use leading to chemical waste, and instability, making it unsuitable for pharmaceutical use.
Innovation Solution
A process involving the use of specific solvents like ketones and ethers, controlled stirring and cooling temperatures, and the addition of aqueous alcoholic potassium base to achieve high purity and stability of Raltegravir potassium Form 3, characterized by specific X-ray diffraction patterns and thermal stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If known processes are used to prepare crystalline Raltegravir potassium Form 3, then the product can be obtained, but it suffers from contamination by other polymorphs and lack of reproducibility
Solution Approach 1:
The patent applies parameter changes by optimizing specific process conditions including maintaining reaction temperature between 0-25°C, using specific molar ratios of Raltegravir to potassium base (0.95:1.05), and controlling solvent volumes to achieve consistent formation of pure Form 3 crystals with reproducible results
Solution Approach 2:
The patent uses an intermediary approach by selecting specific solvents (acetone, methyl ethyl ketone, methyl isobutyl ketone, or their mixtures) that mediate the crystallization process to favor the formation of pure Form 3 while preventing contamination by other polymorphs
2Stability of the object's composition
If known processes are used to prepare crystalline Raltegravir potassium Form 3, then the product can be obtained, but it is unstable and tends to convert to Form 1
Solution Approach 1:
The patent maintains stability by controlling critical parameters including reaction temperature (0-25°C), solvent composition (ketone/ether mixtures), and molar ratios, which create favorable conditions for stable Form 3 crystallization that resists conversion to other polymorphs during storage
Solution Approach 2:
The patent applies preliminary action by ensuring complete reaction of Raltegravir with potassium base before crystallization begins, and by pre-selecting appropriate solvent systems that promote stable Form 3 formation, preventing subsequent polymorph conversion
3Manufacturing precision
If known processes are used to prepare crystalline Raltegravir potassium Form 3, then the product can be obtained, but excessive amounts of solvents are used generating large quantity of chemical waste
Solution Approach 1:
The patent reduces solvent waste by optimizing solvent volumes to minimum required amounts for the reaction and crystallization process, and by selecting solvents with favorable properties that allow efficient recovery and reuse, thereby reducing chemical waste while maintaining high product purity
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process ensures the production of highly pure and stable crystalline Raltegravir potassium Form 3 with greater than 95% purity, maintaining stability at accelerated conditions and suitable for pharmaceutical formulations.
Implementation Method 1
a process involving the use of specific solvents like ketones and ethers, controlled stirring and cooling temperatures, and the addition of aqueous alcoholic potassium base to achieve high purity and stability of Raltegravir potassium Form 3
Data Source
AI summary
The present invention provides improved, commercially viable and consistently reproducible processes for the preparation of pure and stable crystalline Raltegravir potassium Form 3 and pharmaceutical composition thereof.